CardioExchange Archive

August 22nd, 2013

Expert Perspective: Remote Ischemic Preconditioning for CABG

Zhe Zheng, M.D., Ph.D. and Shengshou Hu, M.D.

Dr. Zhe Zheng and Dr. Shengshou Hu, of Fu Wai Hospital in Beijing, discuss the findings from the recent randomized trial conducted in Germany.

---

August 19th, 2013

Selections from Richard Lehman’s Literature Review: August 19th

Richard Lehman, BM, BCh, MRCGP

This week’s topics include treating to risk, not to target; perceived job insecurity as a risk factor for incident CHD; ischemic preconditioning in patients undergoing CABG, and more.

---

August 15th, 2013

Remote Ischemic Preconditioning Beneficial Before CABG

Larry Husten, PHD

For several decades cardiologists have been intrigued by the concept of ischemic preconditioning. A small body of research has consistently found that brief episodes of ischemia appeared to somehow prepare the body to better handle a major episode of ischemia. Now a new study from Germany holds out the promise that deliberate ischemic preconditioning prior […]

---

August 5th, 2013

Poll: What Would You Recommend?

Richard A. Lange, MD, MBA

Take the poll: What would you recommend for a patient who is about to undergo CABG for multivessel CAD and is found to have severe carotid stenosis?

---

April 2nd, 2013

Selections from Richard Lehman’s Literature Review: April 2nd

Richard Lehman, BM, BCh, MRCGP

This week’s topics include the TACT study of chelation therapy, off-pump vs. on-pump CABG, clopidogrel with or without aspirin in those taking oral anticoagulants and undergoing PCI, and more.

---

March 11th, 2013

Two Trials Explore On-Pump Versus Off-Pump Bypass Surgery

Larry Husten, PHD

For more of our ACC.13 coverage of late-breaking clinical trials, interviews with the authors of the most important research, and blogs from our fellows on the most interesting presentations at the meeting, check out our Coverage Headquarters. Two large trials presented at the American College of Cardiology meeting in San Francisco and published simultaneously in the New […]

---

February 25th, 2013

Selections from Richard Lehman’s Literature Review: February 25th

Richard Lehman, BM, BCh, MRCGP

This week’s topics include extended use of apixaban, dabigatran, warfarin, or placebo in VTE, the 5-year follow-up of the SYNTAX study, and more.

---

February 22nd, 2013

SYNTAX After 5 Years: Any Change in Results (or Your Practice)?

Richard A. Lange, MD, MBA and L. David Hillis, MD

The 5 year results of the SYNTAX (SYNergy between percutaneous coronary intervention with TAXus and cardiac surgery) trial are now published.  SYNTAX assessed the optimal revascularization strategy for patients with left main and/or 3-vessel disease by randomly assigning such patients to CABG or PCI (with a first-generation paclitaxel-eluting stent) and then determining the rate of […]

---

January 2nd, 2013

CABG Highly Cost-Effective in Diabetics with Multivessel Disease

Larry Husten, PHD

In November the main results of the FREEDOM trial showed that diabetics with multivessel disease do better with CABG than PCI. Now the findings of the trial’s cost-effectiveness study, published online in Circulation, demonstrate that CABG is also highly cost-effective when compared with PCI. Elizabeth Magnuson and colleagues  found that although CABG initially cost nearly $9000 more than PCI ($34,467 […]

---

December 13th, 2012

Diabetics with Multivessel Disease: FREEDOM with CABG?

Valentin Fuster, MD

Dr. Valentin Fuster answers questions about the FREEDOM trial, which shows that diabetics with multivessel disease had lower rates of death and MI with CABG than with PCI.

---